A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF INTRAVENOUS BRIVARACETAM IN SUBJECTS ¿1 MONTH TO <16 YEARS OF AGE WITH EPILEPSY PHASE 2
Clinical Trial Grant
Administered By
Pediatrics, Neurology
Awarded By
UCB Pharma, Inc.
Start Date
July 3, 2018
End Date
November 30, 2021
Administered By
Pediatrics, Neurology
Awarded By
UCB Pharma, Inc.
Start Date
July 3, 2018
End Date
November 30, 2021